When a hemorrhagic fever with a 49% historical fatality rate re-emerges, the clinical and immunological picture matters enormously — not just for outbreak responders in East Africa, but for pandemic preparedness planners worldwide. Uganda's ninth Sudan virus outbreak in 2025 prompted this comprehensive Lancet Global Health review synthesizing nearly five decades of epidemiological and immunological data from every documented Sudan virus disease (SVD) outbreak since 1976.
The review characterizes SVD's clinical arc with precision: following an average incubation of approximately one week, patients develop influenza-like symptoms that transition into severe diarrheal illness, frequently compounding into cardiorespiratory distress and life-threatening dehydration. Advanced cases progress to coagulopathy, acute kidney and liver injury, and ultimately multiorgan failure. The pooled case-fatality rate across outbreaks through 2022 stands at 49% (95% CI: 39–58%), though the 2025 Ugandan outbreak recorded a notably lower rate of 29% — possibly reflecting improved clinical management or case-detection differences. Viral RNA is detectable in blood from symptom onset and peaks during acute illness, with transmission driven primarily by close contact with symptomatic individuals and their bodily fluids, a pattern that amplifies household and healthcare-setting spread.
From an immunological standpoint, early T-cell activation and Sudan virus-specific antibody responses appear mechanistically linked to survival, while suppressed immune function and dysregulated systemic inflammation correlate with fatal outcomes. Critically, survivors demonstrate durable humoral and cellular immunity lasting up to 15 years post-infection — a finding with significant implications for vaccine design and passive immunotherapy strategies. Sudan virus is a filovirus genus cousin of Ebola virus but antigenically distinct enough that Ebola-targeted vaccines and therapeutics, including rVSV-ZEBOV, offer no cross-protection. The gap between SUDV-specific countermeasure development and that of Ebola virus disease remains substantial. This review is confirmatory in organizing existing outbreak data but analytically significant for highlighting that survival-associated immune correlates are now well enough defined to guide rational vaccine and therapeutic development — a meaningful step forward.